How to buy Synopsys (SNPS) stock from India

Yes, an Indian resident can buy Synopsys — legally, in US dollars, under the RBI's Liberalised Remittance Scheme (LRS). The buying is the easy 10%; tax, estate-tax exposure and position sizing decide your outcome. SNPS pays no dividend, so US withholding and Form 67 are a non-issue. Many Indian VLSI engineers already hold SNPS through RSUs from the Bangalore and Noida centres — this guide covers what changes on an open-market top-up.

The 30-second version

• Legal and simple. Buy SNPS via an India-facing platform (Vested, INDmoney) or a global broker (Interactive Brokers, Rovia). Whole shares or fractional.
• Pure capital-gains play. SNPS has never paid a dividend — US dividend withholding and Form 67 are essentially irrelevant. A clean Section 112 story.
• India tax: hold more than 24 months → 12.5% LTCG (no indexation); sell sooner → your slab rate. Section 112, not the friendlier 112A.
• The trap most miss: directly-held SNPS is a US-situs asset — above $60,000, your estate faces up to 40% US estate tax, with no treaty relief.
• If your thesis is "US tech," QQQ holds SNPS and semi-themed SOXX has it as a top weight — same exposure, no single-stock risk.

Quick facts

Can an Indian resident buy it?	Yes — fully legal under the LRS
Ticker / exchange	SNPS / Nasdaq
How	India-facing platform (Vested, INDmoney) or global broker (IBKR, Rovia)
Minimum	A fraction of one share (fractional matters — SNPS trades in the hundreds)
Dividend	None — never paid, no announced plan to start
India tax on gains	12.5% LTCG after 24 months; else slab (Section 112)
Estate-tax risk	US-situs above $60k means up to 40%, no treaty relief
Annual compliance	Schedule FA disclosure, every year you hold

How to buy it — 3 steps

1. Open an account and finish KYC. India-facing platform (Vested, INDmoney) for a simple INR-funded experience, or a global broker (Interactive Brokers, Rovia) for wider access. File your W-8BEN at onboarding — still good practice even with no current dividend. New to this? Start with how to invest in US stocks from India.
2. Fund it via the LRS. Remit under the LRS (cap: $250,000 per financial year). 20% TCS applies above ten lakh rupees in a year — a creditable prepayment, not a cost. See LRS explained and the LRS and TCS calculator.
3. Place the order. SNPS has never split — one share trades in the high hundreds, so fractional is the easier route if you want an exact rupee amount.

The tax that actually matters

Synopsys pays no dividend, so the 25% US withholding and Form 67 dance — a headache with Microsoft or Apple — does not apply. Your entire tax exposure is on capital gains at sale, under Section 112 (foreign shares don't get the friendlier 112A treatment Indian equity enjoys):

Holding period	Treatment	Rate
24 months or less	Short-term	Your slab rate (up to roughly 30% plus surcharge)
More than 24 months	Long-term	12.5%, no indexation

Worked example. Buy 2 shares at $480 when USD/INR is 86 → cost 82,560 rupees. Sell 27 months later at $560 when USD/INR is 88 → proceeds 98,560 rupees. Taxable gain 16,000 rupees; LTCG at 12.5% = 2,000 rupees. SNPS trades in the high hundreds — fractional matters more than for low-priced names, and a weaker rupee at sale amplifies the gain. Model with the US capital-gains calculator; rules in how US stocks are taxed in India.

The $60,000 estate-tax trap

Directly-held SNPS is a US-situs asset. If the holder dies with over $60,000 of US-situs assets, the estate faces US estate tax up to 40% — and the India-US treaty does not cover estate tax, so no credit or relief. At a share price in the high hundreds, the threshold arrives fast — roughly a hundred shares puts you in the danger zone. The fix (pooled or fund structures) has to be a deliberate choice before the position gets large. Detail: the $60,000 estate-tax trap.

Buy the stock, or get Synopsys through an ETF?

If you want…	Best route
A concentrated bet that SNPS beats EDA peer Cadence	SNPS directly
"US tech / Nasdaq" exposure	QQQ, VOO, or VTI — SNPS inside, smaller than the megacaps
Targeted semiconductor exposure	SOXX — SNPS is a top holding
The least single-stock risk	A broad ETF

Synopsys sits inside QQQ, VOO and VTI, and is a top holding in the semi-themed SOXX — an index fund gives you SNPS proportional to its size, plus hundreds of others, one Schedule FA entry, and cleaner estate-tax treatment via pooled vehicles. Compare routes in direct stocks vs US ETFs and best US ETFs for Indian investors; broader case in US ETFs for Indians.

If you hold SNPS RSUs from work

Synopsys runs large centres in Bangalore, Noida and Hyderabad, so many readers already hold SNPS through RSUs. Two reminders: perquisite tax at vest and capital-gains tax at sale are separate events, and your cost basis is the FMV on vest date. Before topping up on the open market, work through the complete RSU guide for Indians at US multinationals, RSU vesting: the real tax math and sell-to-cover, sell-all or hold. If SNPS RSUs already make up a meaningful slice of net worth, an open-market top-up is leverage on one employer, not diversification.

The business in one screen

What it is: Synopsys is one half of the EDA duopoly (with Cadence) — the software every semiconductor company uses to design chips. Three legs: EDA tools, a fast-growing IP business (ARC processors, foundation IP, USB/PCIe/DDR), and hardware-assisted verification (ZeBu, HAPS). The Ansys acquisition closed in 2025, adding multi-physics simulation (thermal, EM, structural) — a stack Cadence cannot match.

Bull case	Bear case
EDA duopoly — sticky tools, structural pricing power	China export controls (Synopsys flagged more openly than Cadence)
Ansys closed — multi-physics + chip + system simulation in one stack	Ansys integration debt and synergy-realisation risk
Every new AI accelerator and 3D-IC adds more SNPS seats	Premium valuation versus broader semis
Recurring revenue, multi-year contracts; IP a quiet compounder	Customer consolidation (TSMC, Samsung, Intel) bargaining power
ZeBu hardware emulation adds real hardware revenue	Hyperscalers building some in-house EDA tooling

Valuation is in the live widget above — a high-quality compounder priced for continued execution.

Our take

Verdict: BUY — same EDA-duopoly thesis as Cadence, but the Ansys deal gives Synopsys a multi-physics simulation moat Cadence cannot match.

• EDA duopoly economics. SNPS and Cadence sit between TSMC's fabs and every fabless chipmaker — embedded tools, multi-year contracts, structural pricing. AI-chip design and 3D-IC complexity expand the TAM; each new accelerator pulls in more seats, verification cycles and IP licences.
• Ansys is the differentiator. With Ansys closed in 2025, Synopsys is the only EDA vendor offering chip design, system integration and multi-physics simulation in one stack. As chips move to 3D stacking and chiplets, physics-aware design becomes non-optional — Cadence has no equivalent.
• IP is a hidden compounder. ARC processors, foundation IP and interconnect IP throw off recurring royalty-like revenue at high margins, growing with every chip taped out using SNPS tools. Plus ZeBu — more than a software company.

Premium multiple deserved. Fits as a high-conviction satellite for picks-and-shovels AI-chip exposure, without the hyperscaler concentration of GPU or ASIC names.

Compliance note. Vested.blog is not a SEBI-registered Research Analyst. The above is an editorial opinion for educational illustration only — not investment advice and not a regulated stock recommendation. Vested.blog is published by Rovia; the publisher and its affiliates may hold positions in stocks discussed. Make your own decisions or consult a SEBI-registered advisor.

Risks to size for

• China export controls. Synopsys flagged China impact more openly than Cadence; tightening US controls on EDA exports is the single biggest revenue-line risk and moves the stock fast.
• Ansys integration. Closed in 2025, but synergy realisation and deal debt are still being proven — any cross-sell or retention slip pressures the multiple.
• Hyperscaler-internal EDA and customer concentration. Google, Amazon and Meta are quietly building some in-house flows; TSMC, Samsung and Intel drive a large share of advanced-node seats — together these cap growth and bargaining power at the top.
• Currency: USD returns, rupee spending — see the rupee-dollar effect.

Two things people forget

• Schedule FA: disclose SNPS every year you hold it — even if bought and sold within the year, even at a loss, even if from RSU vests. Non-disclosure carries Black Money Act penalties. SNPS pays no dividend, so Form 67 doesn't apply — but Schedule FA is non-negotiable. Use the Schedule FA helper.
• Position size: at a share price in the high hundreds, even a small whole-share ticket is a meaningful rupee amount. Size SNPS as a high-conviction satellite, not a broad-ETF substitute — and if you already hold a big SNPS RSU pile, count it.

Bottom line

Buying SNPS from India is easy and legal. What needs thought: it's a Section-112 capital-gains play (12.5% after 24 months), a US-situs asset with a $60k estate-tax trap, and a high-priced single name that needs disciplined sizing. No dividend means no 25% withholding and no Form 67 — a clean capital-gains story. If your thesis is "AI chip picks-and-shovels," SOXX or QQQ give exposure without the concentration; if it's specifically "EDA duopoly plus Ansys moat," SNPS is the cleanest single-name expression. Start at the US investing hub.

---

This article is general information, not personalised investment, tax, or legal advice. Rules, rates, and thresholds described here are as of 2026 and can change; verify the current position and consult a qualified advisor before acting.